Document 3QKbpJRRrXqVMLMK2djmg1gRy

Bl etnn ova: cTeor Subjects MONTANI Elena (ENV) RE: PFAS request for a meeting. OAcsaarlrJeaIdyNcNo.mmunicated o you in December, please be aware that we have providedyourcontact desesteanitliatlouosuerscopnltarnancetdotrowthaokeisplcaucrereonntl3y pMraerpcahri2n0g22a.fiTrhsitswioraknshooppenfoarnsdtaiknechluoslidveerfsoornumthwehceornecealplt of itnhteerreefsotreedpsrteafkeerhroelddoevresrcabinlaptreorvalidmeeetthienigisn.put to this topic. As such and in this point in time, itis You may find more information about this workshop here: Finally, as also indicated to you earlier, the initiative to prepare a restriction proposalfo a group of PFAS sthuebrsetfaonrceesadivs iasnedintiotiaptriovveiodefaignfroorumpatoifoMneambbouetryoStuartessp,enciofticofutshese oEfurPoFpAeStanoCtohmomsiessMieomnb. eYrouStaartee authorities for more details, please consult Registry of restriction intentions until outcome - ECHA {suropa.eul). Yours sincerely, EDeG ENeVIRoONnMEiNoT n 5U.n1it0089.2BRSUusStSaEiLnaSble chemicals E Tis eE -mail contains thce pcersonal opinions ofthe author and does not necessarly reflect the offical oIeppioniinotndoefvthueeCoofmfmcieslsdieolna. Coopimniisosnioexnprime ic est un avs personnel qu ne reflte pas ncessairement From: @anmalhesitheurcpe.eu S"Teon:tM: OFNriTdAayN,IFeEblreunaar(yE4N,V2)0<2E2le1n:a29MOPNMTANI@ec.europa.eu>; [NI] ca @animalheattheureoup;e {III `Subject: P@AaSn-imraelqhueesatltfhoreuarmoapet.ienug> Dear Ms Montani and [I A`mneidmiaclihneesa,ltvhaEcucrinoepse aisntdhoetahsesrocainaitmiaoln hreeaplrtehsepnrtoidnugctmsaniunfEaucrtoupree.rsWoefaraneimaaBlrusselsbased not-for-profitbodyrepresenting both corporate members and national animal health associations in Europe. It represents both innovators and generics alike, as well as large, medium-sized and small companies. AnimalhealthEurope''s membership covers. 90% of the European market for animal health products. As you may know, some veterinary medicinal products (VMPs), after having been approvedbythe EMA contain PFAS. aHlorweeavdeyri,mapsacatirnesguVltIPofs tehiethReEr AdCuHriRneggtuhleaitrimonan(uRfeagct19u0r7e/o2r00in6)thveairriocuosmpionsiititaitoinv,es aanrde are in direct conflict with the rules in Reg 2019/6 (Veterinary Medicinal Products Regulation entry into force on 28 January 2022. For example the recently launched proposal for restriction of per- and polyfluoro alkyl substances (PFAS) which, given its broad definition of PFAS, threatenas ban on specific VMPs or renders their manufacture impossible as there are no alternatives. E.g. this could eliminate all inhalation anaesthetics currently used in both human and veterinary medicine, and it could cause significant treatment gaps in other areas with implications for animal health but also for public health assomeof the conditions that are treatedby these medicines (e.g. fleas and ticks, and the diseases they carry) can impact human health ifthe animals are left insufficiently treated, or even untreated. As we are aware that you are responsible for this file in DG Envi for the human medicines, and as our issues are quite similar, we would very much valuetodiscuss `with you the particularity of our sector and products, exchaonnwghaet the definition of "essential use " could entail, be consulted by the consulting firm Wood you are `working with and be informed! involved in relevant workshops on the topic. I hope to have an opportunity to discuss these elements with you in February still. Best regards, animalhealth Ng europe Ae5nn0imeraaessttTh,eEwubraorgpes1o68b, .box 8 To Tamporeny Resse: QUEM. Emmabedveusse cy UFklooSnaFaicenbootk:es cn Tcceor comsmh otic: This. esas, ogetheoVilohluauyseoatnnvLiaknetdta:.niaconntai1nasfoermkatsiionn hcaotnmcayombepaconfaindmenatilalhesecpe! eEUihGncocorprd.pDlotsaesPnreoltdyeiuSsnilRymeTngrieotdenia(btCyhUeaPplhRyAOveertriynndrddeatldsea(ahhvseemsayanouetf,iemnSp:erhsWoenccoomhnpotlrayecrvtiethchee ivnagcspoand thQetvy eforemorreeoSrmateioanl, recorded and med ocvith (Ani: check